Comparison · NCT00824512-sae
EGb 761® 120 mg vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. EGb 761® 120 mg vs Placebo: serious adverse events. Trial comparisons, record NCT00824512-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00824512-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0909 | 0.0162 | 0.377 | wilson | |
| Risk in group 2 | 0.0909 | 0.0162 | 0.377 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.296 | 0.296 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 0.0712 | 14.1 | log | |
| Odds ratio, group 1 over group 2 | 1 | 0.0546 | 18.3 | log | |
| Number needed to harm | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | EGb 761® 120 mg | EGb 761 120 mg : EGb 761® 120 mg BID, orally for 12 to 14 weeks | 1 | 11 | EG000 |
| Group 2 | Placebo | Placebo : Placebo 1 tablet BID, orally for 12 to 14 weeks.~Baseline Characteristics data is based on the mITT population, which comprised of the 21 patients. One patient in the placebo group was excluded from the analyses because no assessment of the primary criteria was performed. | 1 | 11 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia
- NCT number
- NCT00824512
- Phases
- PHASE2
- Conditions
- Friedreich Ataxia
- Interventions
- EGb 761 120 mg, Placebo
- Lead sponsor
- Ipsen
- Results first posted
- 2013-05-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00824512?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00824512-sae